IL6ST and metabolic dysfunction-associated steatotic liver disease: Circulating sgp130 levels have also been found to be increased in people with steatotic liver disease and steatohepatitis (metabolic dysfunction–associated steatotic liver disease (MASLD)/metabolic dysfunction–associated steatohepatitis (MASH)), and further increased in diabetes concurrent with steatohepatitis, with clear correlations between HbA1c and sgp130 levels in obesity.27